Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat.
Treatment of Sprague-Dawley rats with the compound LS 2616, a quinoline-3-carboxamide, enhanced the delayed-type hypersensitivity response (DTH) to recall antigens as judged by the specific accumulation of inflammatory cells after challenge with Bordetella pertussis in the pleural space. LS 2616 was effective when given both before sensitization and at the time of secondary antigen challenge. The effect of LS 2616 on DTH was dose-dependent. LS 2616 was highly effective in enhancing DTH in rats with suppressed cell-mediated immunity after treatment with anti-thymocyte globulin or prednisolone, indicating its possible value in the immunosuppressed state.
Stålhandske
T
T
Kalland
T
T
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D000961:Antilymphocyte Serum / Q000276:immunology; D001886:Bordetella pertussis / Q000276:immunology*; D005260:Female; D006912:Hydroxyquinolines / Q000494:pharmacology*; D006968:Hypersensitivity, Delayed; D007114:Immunization; D007375:Interleukin-1 / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D051381:Rats; D011919:Rats, Inbred Strains; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D000961:Antilymphocyte Serum; D006912:Hydroxyquinolines; D007375:Interleukin-1; D007376:Interleukin-2; C045282:roquinimex